Does intravenous dipyridamole administration cause acute renal impairment?

Abstract

Purpose: Dipyridamole increases extracellular adenosine concentrations, and may result a significant decrease on GFR. The aim of the study was detect whether any deterioration occurs in renal function in patients who were undergoing dipyridamole myocardial perfusion scintigraphy. Material and method:94 patients (64 women, 30 men, mean age; 69 ± 10) undergoing dipyridamole myocardial perfusion scintigraphy enrolled to our study. Blood samples were taken from all patients for serum creatinine and cystatin C before and at 4th and 48 hours after the test. The patients were divided into two groups as GFR value higher (group A) and equal or lower (group B) than 60 mL/dk/1.73m² according to GFR calculation modalities. The development and incidence of nephropathy (25% increase in serum creatinine or cystatin C level from the baseline value at 4th and 48th hours after administration of dipyridamole) was determined betweeen the two groups.Result: Group B were significantly elder and more hypertensive than group A. Serum creatinine levels did not exhibit any difference between the groups at 4th and 48th hours in all calculation modalities. Besides that, only 4th hours cystatin C level showed significantly increasing in in patients with MDRD-GFR < 60 mL/ dk/1.73m² whereas 48th hours cystatin C levels did not. Any change in cystatin C levels also were not observed between the groups in other calculation modalities. Conclusion:Dipyridamole myocardial perfusion scintigraphy can be used safely in patients with GFR ≤ 60 mL/dk/1.73m² except end stage renal disease.